Sarepta Therapeutics, Inc. SRPT Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $801.28M-27.4% | $1.1B+157% | $428.43M-55.7% | $966.78M-54.3% | ||
| $138.37M-45.0% | $251.78M-79.8% | $1.25B+22.0% | $1.02B— | ||
| $398.23M-33.8% | $601.99M+50.4% | $400.33M+86.5% | $214.63M+40.3% | ||
| $184.54M-1.8% | $187.99M-1.8% | $191.37M+17.7% | $162.55M-12.7% | ||
| $2.54B-17.4% | $3.07B+19.2% | $2.58B+0.8% | $2.56B-1.8% | ||
| $345.13M+1.4% | $340.34M+49.8% | $227.15M+26.2% | $180.04M-5.8% | ||
| $3.35B-15.5% | $3.96B+21.4% | $3.26B+4.4% | $3.13B-0.6% | ||
| $280.84M+31.0% | $214.44M+30.0% | $164.92M+72.0% | $95.88M+24.9% | ||
| $443.4M+240% | $130.26M+158% | $50.42M-43.5% | $89.24M0.0% | ||
| —— | $0-100% | $105.48M— | $0— | ||
| $1.1B+49.7% | $731.68M+11.9% | $653.66M+5.5% | $619.6M+36.9% | ||
| $2.21B-9.3% | $2.44B+1.3% | $2.41B-12.3% | $2.74B+23.6% | ||
| $11K+10.0% | $10K+11.1% | $9K0.0% | $9K0.0% | ||
| -$4.88B-15.8% | -$4.21B+5.3% | -$4.45B-13.7% | -$3.91B-21.9% | ||
| $1.14B-25.3% | $1.53B+77.8% | $859.34M+123% | $384.95M-58.5% | ||
| $3.35B-15.5% | $3.96B+21.4% | $3.26B+4.4% | $3.13B-0.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Sarepta Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 4.63 — current assets exceed current liabilities.
- Where does Sarepta Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Sarepta Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.